Autres langues Takeda Pharmaceutical Company Limited London S.E.

Actions

0A87

US8740602052

Temps Différé London S.E. Autres places de cotation 16:57:19 26/06/2024			Varia. 5j.	Varia. 1 janv.
12,88 ^USD	+1,13 %		+1,89 %	-9,43 %

25/06	Les CDC américains alertent les prestataires de soins de santé sur l'augmentation du nombre de cas de dengue	RE
25/06	Un médicament anticancéreux de Takeda reçoit l'approbation de la Commission européenne	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Takeda anuncia el nombramiento de nuevos cargos directivos	05:58
Takeda kündigt neue Besetzung der Direktorenposten an	01:44
TAKEDA PHARMACEUTICAL : Form 6 K	26/06
Takeda Pharmaceutical : Announces New Assignments of Directors Form 6 K	26/06
Takeda Announces New Assignments of Directors	26/06
US CDC alerts healthcare providers of increase in dengue cases	25/06
Takeda's Cancer Drug Gets European Commission Approval	25/06
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24/06
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24/06
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21/06
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	21/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Takeda Pharmaceutical Company Limited London S.E.

Actions

0A87

US8740602052

Autres langues

Filtres